Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes

We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials when the bivariate continuous outcomes are described using nonlinear regression models. We determine upper bounds on the required number of different doses and provide conditions under which the boun...

Descripción completa

Detalles Bibliográficos
Autores principales: Schorning, K, Dette, H, Kettelhake, K, Wong, W K, Bretz, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Miscellanea
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793717/
https://www.ncbi.nlm.nih.gov/pubmed/29430043
http://dx.doi.org/10.1093/biomet/asx057
_version_ 1783297015129571328
author Schorning, K
Dette, H
Kettelhake, K
Wong, W K
Bretz, F
author_facet Schorning, K
Dette, H
Kettelhake, K
Wong, W K
Bretz, F
author_sort Schorning, K
collection PubMed
description We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials when the bivariate continuous outcomes are described using nonlinear regression models. We determine upper bounds on the required number of different doses and provide conditions under which the boundary points of the design space are included in the optimal design. We provide an analytical description of minimally supported optimal designs and show that they do not depend on the correlation between the bivariate outcomes.
format Online
Article
Text
id pubmed-5793717
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-57937172018-12-01 Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes Schorning, K Dette, H Kettelhake, K Wong, W K Bretz, F Biometrika Miscellanea We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials when the bivariate continuous outcomes are described using nonlinear regression models. We determine upper bounds on the required number of different doses and provide conditions under which the boundary points of the design space are included in the optimal design. We provide an analytical description of minimally supported optimal designs and show that they do not depend on the correlation between the bivariate outcomes. Oxford University Press 2017-12 2017-10-09 /pmc/articles/PMC5793717/ /pubmed/29430043 http://dx.doi.org/10.1093/biomet/asx057 Text en © 2017 Biometrika Trust
spellingShingle Miscellanea
Schorning, K
Dette, H
Kettelhake, K
Wong, W K
Bretz, F
Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title_full Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title_fullStr Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title_full_unstemmed Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title_short Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
title_sort optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
topic Miscellanea
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793717/
https://www.ncbi.nlm.nih.gov/pubmed/29430043
http://dx.doi.org/10.1093/biomet/asx057
work_keys_str_mv AT schorningk optimaldesignsforactivecontrolleddosefindingtrialswithefficacytoxicityoutcomes
AT detteh optimaldesignsforactivecontrolleddosefindingtrialswithefficacytoxicityoutcomes
AT kettelhakek optimaldesignsforactivecontrolleddosefindingtrialswithefficacytoxicityoutcomes
AT wongwk optimaldesignsforactivecontrolleddosefindingtrialswithefficacytoxicityoutcomes
AT bretzf optimaldesignsforactivecontrolleddosefindingtrialswithefficacytoxicityoutcomes

Ejemplares similares